Drug / Drugs / Medicine

Phase 2 data for Roche's lymphoma ADC doesn't disappoint

Posted on: Dec 11, 2017   |   Posted by: Biotech Mag

With breakthrough designation from the FDA and priority medicine status in the EU, expectations for Roche's antibody-drug conjugate for non-Hodgkin lymphoma polatuzumab vedotin...